Ascendis Pharma A/S $ASND Shares Sold by Tema Etfs LLC

Key Points

• Tema Etfs LLC reduced its stake in Ascendis Pharma A/S by 67.9%, bringing its holdings to 6,106 shares worth $952,000.
• Several institutional investors, including HighTower Advisors LLC, significantly increased their positions in Ascendis Pharma, highlighting interest from the investment community.
• Ascendis Pharma A/S reported better-than-expected earnings, with an earnings per share of ($0.93) against a consensus estimate of ($1.42), and achieved $216.28 million in revenue for the quarter.

Tema Etfs LLC lessened its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 67.9% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,106 shares of the biotechnology company's stock after selling 12,934 shares during the period. Tema Etfs LLC's holdings in Ascendis Pharma A/S were worth $952,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Trexquant Investment LP raised its stake in shares of Ascendis Pharma A/S by 61.7% during the first quarter. Trexquant Investment LP now owns 43,760 shares of the biotechnology company's stock valued at $6,820,000 after acquiring an additional 16,693 shares in the last quarter. Tri Locum Partners LP bought a new stake in shares of Ascendis Pharma A/S during the first quarter valued at approximately $5,038,000. Campbell & CO Investment Adviser LLC raised its stake in shares of Ascendis Pharma A/S by 116.0% during the first quarter. Campbell & CO Investment Adviser LLC now owns 13,036 shares of the biotechnology company's stock valued at $2,032,000 after acquiring an additional 7,001 shares in the last quarter. Resolute Capital Asset Partners LLC grew its holdings in shares of Ascendis Pharma A/S by 46.3% during the first quarter. Resolute Capital Asset Partners LLC now owns 167,500 shares of the biotechnology company's stock valued at $26,107,000 after buying an additional 53,000 shares during the last quarter. Finally, Q Global Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 13.4% during the first quarter. Q Global Advisors LLC now owns 248,887 shares of the biotechnology company's stock valued at $38,792,000 after buying an additional 29,428 shares during the last quarter.

Ascendis Pharma A/S Trading Up 3.9%

Shares of Ascendis Pharma A/S stock traded up $7.66 during trading hours on Tuesday, reaching $201.93. The stock had a trading volume of 236,209 shares, compared to its average volume of 489,637. The stock's 50 day moving average is $180.56 and its 200 day moving average is $166.70. The firm has a market capitalization of $12.36 billion, a PE ratio of -39.28 and a beta of 0.39. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $203.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping analysts' consensus estimates of ($1.42) by $0.49. The firm had revenue of $216.28 million during the quarter, compared to analyst estimates of $163.17 million. As a group, sell-side analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ASND shares. Royal Bank Of Canada boosted their price objective on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an "outperform" rating in a report on Friday, August 8th. JPMorgan Chase & Co. boosted their price objective on shares of Ascendis Pharma A/S from $254.00 to $260.00 and gave the company an "overweight" rating in a report on Tuesday, August 19th. Wedbush boosted their target price on shares of Ascendis Pharma A/S from $212.00 to $220.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Cowen restated a "buy" rating on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Finally, Cantor Fitzgerald boosted their target price on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. Fifteen research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $244.36.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.